MX361565B - Metodos de tratamiento de fibrosis y canceres. - Google Patents

Metodos de tratamiento de fibrosis y canceres.

Info

Publication number
MX361565B
MX361565B MX2015009251A MX2015009251A MX361565B MX 361565 B MX361565 B MX 361565B MX 2015009251 A MX2015009251 A MX 2015009251A MX 2015009251 A MX2015009251 A MX 2015009251A MX 361565 B MX361565 B MX 361565B
Authority
MX
Mexico
Prior art keywords
cancers
fibrosis
treatment
methods
carboxydimethylmethyloxyphenyl
Prior art date
Application number
MX2015009251A
Other languages
English (en)
Other versions
MX2015009251A (es
Inventor
Hanf Rémy
Hum Dean
Walczak Robert
Noel Benoît
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of MX2015009251A publication Critical patent/MX2015009251A/es
Publication of MX361565B publication Critical patent/MX361565B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al uso del compuesto 1-[4-metiltiofenil]-3-[3,5-dimeti-4-carboxidimetilmetiloxifenil]p rop-2-en-1-ona para tratar enfermedades fibróticas y cánceres.
MX2015009251A 2013-01-18 2014-01-20 Metodos de tratamiento de fibrosis y canceres. MX361565B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305067 2013-01-18
PCT/EP2014/051060 WO2014111584A1 (en) 2013-01-18 2014-01-20 Methods of treatment of fibrosis and cancers

Publications (2)

Publication Number Publication Date
MX2015009251A MX2015009251A (es) 2015-10-15
MX361565B true MX361565B (es) 2018-12-11

Family

ID=47628079

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009251A MX361565B (es) 2013-01-18 2014-01-20 Metodos de tratamiento de fibrosis y canceres.

Country Status (26)

Country Link
US (2) US20150352065A1 (es)
EP (1) EP2948137B1 (es)
JP (1) JP6218854B2 (es)
KR (1) KR102196277B1 (es)
CN (1) CN105120855B (es)
AU (1) AU2014206781B2 (es)
CA (1) CA2897258C (es)
CY (1) CY1121156T1 (es)
DK (1) DK2948137T3 (es)
EA (1) EA031718B1 (es)
ES (1) ES2702038T3 (es)
HK (1) HK1214773A1 (es)
HU (1) HUE042569T2 (es)
IL (1) IL239715B (es)
LT (1) LT2948137T (es)
MD (1) MD4629B1 (es)
MX (1) MX361565B (es)
NZ (1) NZ709420A (es)
PH (1) PH12015501566B1 (es)
PL (1) PL2948137T3 (es)
PT (1) PT2948137T (es)
SG (1) SG11201505281PA (es)
SI (1) SI2948137T1 (es)
TR (1) TR201819042T4 (es)
WO (1) WO2014111584A1 (es)
ZA (1) ZA201505151B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2948137T1 (sl) 2013-01-18 2019-01-31 Genfit Metode zdravljenja fibroz in rakov
WO2017147276A1 (en) * 2016-02-23 2017-08-31 Celgene Corporation Methods of treating intestinal fibrosis using smad7 inhibition
CN110536682B (zh) * 2017-04-18 2023-01-06 基恩菲特公司 依拉非诺或其衍生物与抗nash、抗纤维化或抗胆汁淤积药剂的组合
TW202019870A (zh) 2018-08-03 2020-06-01 法商Ｇｅｎｆｉｔ公司 艾拉菲諾鹽
GB201901507D0 (en) * 2019-02-04 2019-03-27 St Georges Hospital Medical School New treatment
AU2021219286A1 (en) 2020-02-10 2022-09-22 Genfit Polymorphs of elafibranor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7736677B2 (en) * 2001-06-20 2010-06-15 Metaproteomics, Llc Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
FR2841784B1 (fr) * 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2841900B1 (fr) 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
FR2857361B1 (fr) * 2003-07-08 2005-09-09 Genfit S A PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one
CA2781451C (en) * 2009-11-26 2019-04-16 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
ES2384060B1 (es) * 2010-03-24 2013-09-23 Lipotec S.A. Cápsulas de nanopartículas lipídicas.
SI2948137T1 (sl) 2013-01-18 2019-01-31 Genfit Metode zdravljenja fibroz in rakov

Also Published As

Publication number Publication date
EP2948137B1 (en) 2018-11-14
MX2015009251A (es) 2015-10-15
NZ709420A (en) 2020-04-24
PH12015501566A1 (en) 2015-09-21
AU2014206781B2 (en) 2018-08-23
TR201819042T4 (tr) 2019-01-21
JP6218854B2 (ja) 2017-10-25
SI2948137T1 (sl) 2019-01-31
KR20150114497A (ko) 2015-10-12
IL239715B (en) 2019-06-30
SG11201505281PA (en) 2015-08-28
PT2948137T (pt) 2018-12-20
US20150352065A1 (en) 2015-12-10
CN105120855A (zh) 2015-12-02
EP2948137A1 (en) 2015-12-02
HUE042569T2 (hu) 2019-07-29
US20170239213A1 (en) 2017-08-24
ZA201505151B (en) 2016-07-27
HK1214773A1 (zh) 2016-08-05
US10792277B2 (en) 2020-10-06
EA031718B1 (ru) 2019-02-28
JP2016506913A (ja) 2016-03-07
AU2014206781A1 (en) 2015-07-16
MD4629B1 (ro) 2019-05-31
EA201591345A1 (ru) 2015-11-30
LT2948137T (lt) 2018-12-27
PH12015501566B1 (en) 2015-09-21
KR102196277B1 (ko) 2020-12-29
CA2897258A1 (en) 2014-07-24
MD20150076A2 (ro) 2015-11-30
IL239715A0 (en) 2015-08-31
CA2897258C (en) 2021-02-02
DK2948137T3 (en) 2019-01-07
PL2948137T3 (pl) 2019-02-28
CN105120855B (zh) 2019-05-07
ES2702038T3 (es) 2019-02-27
CY1121156T1 (el) 2020-05-29
WO2014111584A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
PH12018502056A1 (en) Methods of treatment of cholestatic diseases
HK1213925A1 (zh) 用於治療癌症的涉及抗密蛋白 抗體的組合療法
WO2015073587A3 (en) Synthetic membrane-receiver complexes
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
PH12015501566A1 (en) Methods of treatment of fibrosis and cancers
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
MX2021007268A (es) Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
NZ631701A (en) Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases
HK1220324A1 (zh) 用於治療血管緊張素相關疾病的方法、化合物和組合物
PH12017500864A1 (en) Anti-notch1 antibodies
TN2015000519A1 (en) Small molecule inhibitors of fibrosis
HK1223923A1 (zh) 用於治療癌症的作為 突變體抑制劑的 -或 -二氨基嘧啶化合物
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
EP3089745A4 (en) Compounds, compositions, and methods for the treatment of cancers
MX2020011766A (es) Metodos de administracion de tratamiento antifibrotico.
WO2014180882A3 (en) Treatment of brain metastasis from cancer
IN2013MU03429A (es)
UA88100U (ru) Применение экстракта из листьев мать-и-мачехи (tussilago farfara l.) как противоязвенного средства

Legal Events

Date Code Title Description
FG Grant or registration